P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratificationJeanine Arkenbosch, Annemarie C. de Vries, Oddeke van Ruler et al.|Journal of Crohn s and Colitis|2022Cited by 3
P190 Identification of clinical risk factors for postoperative endoscopic recurrence in Crohn’s disease: a prospective, multicenter cohort studyM Bak, Andrica de Vries, Evelien Beelen et al.|Journal of Crohn s and Colitis|2024Cited by 1
P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, Fenna M. Jansen et al.|Journal of Crohn s and Colitis|2023Cited by 0
P228 Prehabilitation strategies prior to ileocolonic resection in Crohn’s disease in a prospective cohort study: a missed window of opportunity?Marit F.E. Ruiterkamp, Andrica de Vries, Jeanine Arkenbosch et al.|Journal of Crohn s and Colitis|2021Cited by 0
P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trialMartine Devillers, Frank Hoentjen, L van Lierop et al.|Journal of Crohn s and Colitis|2025Cited by 0